 |
Amazon
SKIN-P SUPPORT*
120 capsules (650 mg each)
Buy Now
|
|
A synergistic formula of rainforest botanicals that are traditionally used in South America for the skin during times of special needs.* For more information on the individual ingredients in Amazon Skin-P Support, follow the links provided below to the plant database files in the Tropical Plant Database.
Each rainforest botanical in this professional formula has been sustainably harvested in the Amazon Rainforest. Click here to learn more about our rainforest ingredients and wild harvesting methods. This product contains no binders, fillers, or exipients and is 100% finely milled natural plants. This product is backed by Raintree's Unconditional Guarantee.
Ingredients: A proprietary blend of samambaia, pau d'arco, cat's claw, boldo, fedegoso, sarsaparilla, suma, and bitter melon. This formula is 100% pure natural ground plants. No binders, fillers or other additives are used. These plants have grown naturally in the richness of the Amazon without any pesticides or fertilizers and they are non-irradiated and non-fumigated.
Suggested Use: Take 2-3 capsules twice daily.
Contraindications: - Not to be used during pregnancy or while breast-feeding.
- Do not use in combination with digitalis drugs.
- Cat's claw has an immunostimulant activity and is contraindicated before or following any organ or bone marrow transplant or skin graft.
Drug Interactions: May potentiate digitalis. Several plants in this formula have been reported to have an liver detoxing effect and therefore may speed the clearance of some drugs from the liver.
Other Practitioner Observations:
- Several plants in this formula have demonstrated antimicrobial activity in laboratory tests. Long term use may lead to die-off of friendly bacteria in the digestive tract. Supplementation with probiotics and digestive enzymes is advisable when this formula is used for longer than 30 days.
- Several plants in this formula have been documented to slightly reduce blood pressure in animal studies. Individuals with low blood pressure should be monitored for this possible effect.
- Bitter melon has been documented to reduce blood sugar levels. Those individuals with hypoglycemia, or those on medications to reduce blood sugar level should be monitored for this possible effect.
A 120 capsule bottle is $29.95 each
Or buy 3 bottles for $28.95 each
Or buy 6 bottles for $26.95 each
Buy Now
Print a PDF Amazon Skin-P Support Brochure
Please note that this is a professional product offered by health practitioners and it is not available in retail stores. Click here to see a list of practitioners who use our products.
|
|
Third-Party Published Research*
This proprietary Raintree product has not been the subject of any clinical research. A partial listing of third-party published research on each herbal ingredient in the formula is shown below. Please refer to the plant database files by clicking on the plant names below to see all available documentation and research on each plant ingredient.
Samambaia (Polypodium sp)
Reyes, E., et al. “Systemic immunomodulatory effects of Polypodium leucotomos as an adjuvant to PUVA
therapy in generalized vitiligo: A pilot study.” J. Dermatol. Sci. 2006 Jan 16;
Navarro-Blasco, F. J., et al. “Modification of the inflammatory activity of psoriatic arthritis in patients treated with
extract of Polypodium leucotomos (Anapsos).” Br. J. Rheumatol. 1998; 37(8): 912.
Vasange, M., et al. “A sulphonoglycolipid from the fern Polypodium decumanum and its effect on the platelet
activating factor receptor in human neutrophils.” J. Pharm. Pharmacol. 1997; 49(5): 562–617.
Vasange, M., et al. “Flavonoid constituents of two Polypodium species (Calaguala) and their effect on the
elastase release in human neutrophils.” Planta Med. 1997; 63(6): 511–17.
Capote, R., et al. “Polypodium leucotomos extract inhibits trans-urocanic acid photoisomerization and
photodecomposition.” J. Photochem. Photobiol. B. 2005 Dec 30;
Middelkamp-Hup, M. A., et al. “Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of
human skin.” J. Am. Acad. Dermatol. 2004 Dec; 51(6): 910-8.
Middelkamp-Hup, M. A., et al. “Orally administered Polypodium leucotomos extract decreases psoralen-UVA-
induced phototoxicity, pigmentation, and damage of human skin.” J. Am. Acad. Dermatol. 2004; 50(1): 41-9.
Philips, N., et al. “Predominant effects of Polypodium leucotomos on membrane integrity, lipid peroxidation,
and expression of elastin and matrixmetalloproteinase-1 in ultraviolet radiation exposed fibroblasts, and
keratinocytes.” J. Dermatol. Sci. 2003 Jun; 32(1): 1-9.
Gonzalez, S., et al. “Topical or oral administration with an extract of Polypodium leucotomos prevents acute
sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin.”
Photodermatol. Photoimmunol. Photomed. 1997; 13(1–2): 50–60.
Vasange, M., et al. “The fern Polypodium decumanum, used in the treatment of psoriasis, and its fatty acid
constituents as inhibitors of leukotriene B4 formation.” Prostaglandins Leukotrienes Essent. Fatty Acids 1994;
50: 279–284.
Tuominen, M., et al. “Effects of calaguala and an active principle, adenosine, on platelet activating factor.”
Planta Med. 1992; 58(4): 306–10.
Jimenez, D., et al. “Anapsos, an antipsoriatic drug, in atopic dermatitis.” Allergol. Immunopathol. 1987;
15(4):185–9.
Jimenez, D., et al. “Anapsos modifies immunological parameters and improves the clinical course in atopic
dermatitis.” Dermatologica 1986; 173(3):154–5.
Pineiro Alvarez, B. “2 years personal experience in anapsos treatment of psoriasis in various clinical forms.”
Med. Cutan. Ibero. Lat. Am. 1983; 11(1): 65–72.
Vargas, J., et al. “Anapsos, an antipsoriatic drug which increases the proportion of suppressor cells in human
peripheral blood.” Ann. Immunol. 1983; 134C(3):393–400.
Del Pino Gamboa, J., et al. “Comparative study between 120 mg. of anapsos and a placebo in 37 psoriasis
patients.” Med. Cutan. Ibero. Lat. Am. 1982; 10(3): 203–8.
Capella Perez, M. C., et al. “Double-blind study using ‘anapsos’ 120 mg. in the treatment of psoriasis.” Actas
Dermosifiliogr. 1981; 72(9-10): 487-94.
Mercadal Peyri, O., et al. “Preliminary communication on the treatment of psoriasis with anapsos.” Actas
Dermosifiliogr. 1981; 72(1–2): 65–8.
Padilla, H. C. “A new agent (hydrophilic fraction of Polypodium leucotomos) for management of psoriasis.” Int.
J. Dermatol. 1974; 13(5): 276–82.
Pau d'arco (Tabebuia impetiginosa)
Muller, K., et al. "Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth."
J. Nat. Prod. 1999; 62(8): 1134-36.
Miranda F. G., et al. “Antinociceptive and antiedematogenic properties and acute toxicity of Tabebuia
avellanedae Lor. ex Griseb. inner bark aqueous extract.” BMC Pharmacol. 2001; 1(1): 6.
Park, B. S., et al. “Antioxidant activity and characterization of volatile constituents of Taheebo (Tabebuia
impetiginosa Martius ex DC).” J. Agric. Food Chem. 2003; 51(1): 295-300.
Cat's Claw (Uncaria tomentosa)
Sheng, Y., et al. “An active ingredient of Cat's Claw water extracts: identification and efficacy of quinic acid.” J.
Ethnopharmacol. 2005 Jan 15; 96(3): 577-84.
Goncalves, C., et al. “Antioxidant properties of proanthocyanidins of Uncaria tomentosa bark decoction: a
mechanism for anti-inflammatory activity.” Phytochemistry. 2005; 66(1): 89-98.
Sandoval, M., et al., “Anti-inflammatory and antioxidant activities of cat’s claw (Uncaria tomentosa and Uncaria
guianensis) are independent of their alkaloid content." Phytomedicine. 2002; 9(4): 325–37.
Boldo (Peumus boldus)
Estelles, R., et al. “Effect of boldine, secoboldine, and boldine methine on angiotensin II-induced neutrophil
recruitment in vivo.” J. Leukoc. Biol. 2005 Sep; 78(3): 696-704.
Backhouse, N., et al. “Anti-inflammatory and antipyretic effects of boldine.” Agents Actions 1994; 42(3–4):
114–17.
Ivorra, M. D., et al. “Different mechanism of relaxation induced by aporphine alkaloids in rat uterus.” J. Pharm.
Pharmacol. 1993; 45(5): 439–43.
Lanhers, M. C., et al. “Hepatoprotective and anti-inflammatory effects of a traditional medicinal plant of Chile,
Peumus boldus.” Planta Med. 1991; 57(2): 110–15.
Fedegoso (Cassia occidentalis)
Samy, R. P., et al. “Antibacterial activity of some folklore medicinal plants used by tribals in Western Ghats of
India.” J. Ethnopharmacol. 2000; 69(1): 63–71.
Anesini, C., et al. “Screening of plants used in Argentine folk medicine for antimicrobial activity.” J.
Ethnopharmacol. 1993; 39(2): 119–28.
Caceres, A., et al. “Plants used in Guatemala for the treatment of dermatophytic infections. 1. Screening for
antimycotic activity of 44 plant extracts.” J. Ethnopharmacol. 1991; 31(3): 263–76.
Hussain, H., et al. “Plants in Kano ethomedicine: screening for antimicrobial activity and alkaloids.” Int. J.
Pharmacog. 1991; 29(1): 51–6.
Gaind, K. N., et al. “Antibiotic activity of Cassia occidentalis.” Indian J. Pharmacy 1966; 28(9): 248–50.
Sarsaparilla (Smilax officinalis)
Juhlin, L., et al. “The influence of treatment and fibrin microclot generation in psoriasis.” Br. J. Dermatol. 1983;
108: 33–7.
Rollier, R. “Treatment of lepromatous leprosy by a combination of DDS and sarsaparilla (Smilax ornata)." Int. J.
Leprosy 1959; 27: 328–40.
Thurman, F. M. “The treatment of psoriasis with sarsaparilla compound.” New England Journal of Medicine
1942; 337: 128–33.
Ma, D., et al. ”Effect of sarsasapogenin and its derivatives on the stimulus coupled responses of human
neutrophils.” Clin. Chim. Acta. 2001 Dec; 314(1-2): 107-12.
Chu, K. T., et al. “Smilaxin, a novel protein with immunostimulatory, antiproliferative, and HIV-1-reverse
transcriptase inhibitory activities from fresh Smilax glabra rhizomes.” Biochem. Biophys. Res. Commun. 2005
Dec; 340(1): 118.
Suma (Pfaffia paniculata)
Mazzanti, G., et al. “Analgesic and anti-inflammatory action of Pfaffia paniculata (Martius) Kuntze." Phytother.
Res. 1994; 8(7): 413-16.
Mazzanti, G., et al. “Anti-inflammatory activity of Pfaffia paniculata (Martius) Kuntze and Pfaffia stenophylla
(Sprengel) Stuchl." Pharmacol. Res. 1993; 27(1): 91–92.
Meybeck, A. et al. Use of an ecdysteroid for the preparation of cosmetic or dermatological compositions
intended, in particular, for strengthening the water barrier function of the skin or for the preparation of a skin cell
culture medium, as well as to the compositions. U.S. patent # 5,609,873. March 11, 1997.
Bitter Melon (Momordica charantia)
Schmourlo, G., et al. “Screening of antifungal agents using ethanol precipitation and bioautography of
medicinal and food plants.” J. Ethnopharmacol. 2005 Jan; 96(3): 563-8.
Khan, M. R., et al. “Momordica charantia and Allium sativum: Broad spectrum antibacterial activity.” Korean J.
Pharmacog. 1998; 29(3): 155–58.
Omoregbe, R. E., et al. “Antimicrobial activity of some medicinal plants’ extracts on Escherichia coli,
Salmonella paratyphi and Shigella dysenteriae.” Afr. J. Med. Med. Sci. 1996; 25(4): 373–75.
|
* The statements contained herein have not been evaluated
by the Food and Drug Administration.
This product is
not intended to treat, cure, mitigate or prevent any disease.
Please refer to our Conditions of Use for this web site and product.
Thank you for your support and
for choosing a Raintree product!
Raintree Nutrition, Inc.
3579 Hwy 50 East, Suite 222
Carson City, NV 89701
(800) 780-5902
(775) 841-4142
(775) 841-4022 Fax
Return to Main Product Page
    
© Copyrighted 1996
to present by Raintree Nutrition, Inc., Carson City, NV 89701. All rights reserved.
Please read the Conditions of Use, Copyright Statement and our Privacy Policy for this web page and web site.
Updated 12-31-06
|